User login
Key clinical point: Patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (methotrexate-IR) who initiated upadacitinib vs adalimumab spent a longer time in improved disease states and reported faster achievement of treatment targets.
Major finding: Patients initially receiving upadacitinib vs adalimumab spent 19% vs 14% of the time over 48 weeks in clinical disease activity index remission (nominal P = .012) and achieved the 28-joint disease activity score using C-reactive protein of <2.6/≤3.2 approximately 6-8 weeks (median time) earlier.
Study details: Findings are from a post hoc analysis including patients with RA and methotrexate-IR from the phase 3 SELECT-COMPARE trial who were randomly assigned to receive upadacitinib (n = 651) or adalimumab (n = 327) with background methotrexate.
Disclosures: The trial was funded by AbbVie, Inc. Five authors declared being employees of and may own stocks or options in AbbVie. The other authors reported ties with various sources, including AbbVie.
Source: Mysler E et al. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: Post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford). 2022 (Aug 26). Doi: 10.1093/rheumatology/keac477
Key clinical point: Patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (methotrexate-IR) who initiated upadacitinib vs adalimumab spent a longer time in improved disease states and reported faster achievement of treatment targets.
Major finding: Patients initially receiving upadacitinib vs adalimumab spent 19% vs 14% of the time over 48 weeks in clinical disease activity index remission (nominal P = .012) and achieved the 28-joint disease activity score using C-reactive protein of <2.6/≤3.2 approximately 6-8 weeks (median time) earlier.
Study details: Findings are from a post hoc analysis including patients with RA and methotrexate-IR from the phase 3 SELECT-COMPARE trial who were randomly assigned to receive upadacitinib (n = 651) or adalimumab (n = 327) with background methotrexate.
Disclosures: The trial was funded by AbbVie, Inc. Five authors declared being employees of and may own stocks or options in AbbVie. The other authors reported ties with various sources, including AbbVie.
Source: Mysler E et al. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: Post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford). 2022 (Aug 26). Doi: 10.1093/rheumatology/keac477
Key clinical point: Patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (methotrexate-IR) who initiated upadacitinib vs adalimumab spent a longer time in improved disease states and reported faster achievement of treatment targets.
Major finding: Patients initially receiving upadacitinib vs adalimumab spent 19% vs 14% of the time over 48 weeks in clinical disease activity index remission (nominal P = .012) and achieved the 28-joint disease activity score using C-reactive protein of <2.6/≤3.2 approximately 6-8 weeks (median time) earlier.
Study details: Findings are from a post hoc analysis including patients with RA and methotrexate-IR from the phase 3 SELECT-COMPARE trial who were randomly assigned to receive upadacitinib (n = 651) or adalimumab (n = 327) with background methotrexate.
Disclosures: The trial was funded by AbbVie, Inc. Five authors declared being employees of and may own stocks or options in AbbVie. The other authors reported ties with various sources, including AbbVie.
Source: Mysler E et al. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: Post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford). 2022 (Aug 26). Doi: 10.1093/rheumatology/keac477